ritanserin has been researched along with Obesity in 5 studies
Ritanserin: A selective and potent serotonin-2 antagonist that is effective in the treatment of a variety of syndromes related to anxiety and depression. The drug also improves the subjective quality of sleep and decreases portal pressure.
ritanserin : A thiazolopyrimidine that is 5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one which is substituted at position 7 by a methyl group and at position 6 by a 2-{4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl}ethyl group. A potent and long-acting seratonin (5-hydroxytryptamine, 5-HT) antagonist of the subtype 5-HT2 (Ki = 0.39 nM), it is used in the treatment of a variety of disorders including anxiety, depression and schizophrenia. It has little sedative action.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "In order to study the hypothesized impairment of the serotoninergic system in human obesity, an insulin tolerance test (ITT) was carried out on 12 obese normoprolactinemic women and on 6 normal-weight women before (A) and after (B) the administration of a serotoninergic drug, fenfluramine (60 mg twice a day per os for 7 days)." | 7.67 | Effects of fenfluramine and ritanserin on prolactin response to insulin-induced hypoglycemia in obese patients: evidence for failure of the serotoninergic system. ( Argenio, GF; Bernini, GP; Del Corso, C; Franchi, F; Luisi, M; Sgrò, M; Vivaldi, MS, 1989) |
| "To elucidate the role of serotonin in the maintenance of normal breathing and upper airway (UA) patency in obesity, we studied the effects of systemic administration of ritanserin, a serotonin (5-HT) 2A and 2C receptor antagonist, on ventilation (V E) during room air breathing and during hypoxic (10% O2) and hypercapnic (4% CO2) ventilatory challenges in awake young (6-8 wk) and older (7-8 mo) obese and lean Zucker (Z) rats." | 3.71 | Serotonergic modulation of ventilation and upper airway stability in obese Zucker rats. ( Farkas, GA; Krasney, JA; Lee, SD; Magalang, UJ; Nakano, H, 2001) |
| "In order to study the hypothesized impairment of the serotoninergic system in human obesity, an insulin tolerance test (ITT) was carried out on 12 obese normoprolactinemic women and on 6 normal-weight women before (A) and after (B) the administration of a serotoninergic drug, fenfluramine (60 mg twice a day per os for 7 days)." | 3.67 | Effects of fenfluramine and ritanserin on prolactin response to insulin-induced hypoglycemia in obese patients: evidence for failure of the serotoninergic system. ( Argenio, GF; Bernini, GP; Del Corso, C; Franchi, F; Luisi, M; Sgrò, M; Vivaldi, MS, 1989) |
| "Ritanserin is a new selective 5-HT2 blocker receptor agent." | 2.67 | Impaired growth hormone response to insulin-induced hypoglycaemia in obese patients: restoration blocked by ritanserin after fenfluramine administration. ( Argenio, GF; Bernini, GP; Birindelli, R; Del Corso, C; Franchi, F; Luisi, M; Vivaldi, MS, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Peng, Y | 1 |
| McCorvy, JD | 1 |
| Harpsøe, K | 1 |
| Lansu, K | 1 |
| Yuan, S | 1 |
| Popov, P | 1 |
| Qu, L | 1 |
| Pu, M | 1 |
| Che, T | 1 |
| Nikolajsen, LF | 1 |
| Huang, XP | 1 |
| Wu, Y | 1 |
| Shen, L | 1 |
| Bjørn-Yoshimoto, WE | 1 |
| Ding, K | 1 |
| Wacker, D | 1 |
| Han, GW | 1 |
| Cheng, J | 1 |
| Katritch, V | 1 |
| Jensen, AA | 1 |
| Hanson, MA | 1 |
| Zhao, S | 1 |
| Gloriam, DE | 1 |
| Roth, BL | 1 |
| Stevens, RC | 1 |
| Liu, ZJ | 1 |
| Squadrito, F | 1 |
| Calapai, G | 1 |
| Cucinotta, D | 1 |
| Altavilla, D | 1 |
| Zingarelli, B | 1 |
| Ioculano, M | 1 |
| Urna, G | 1 |
| Sardella, A | 1 |
| Campo, GM | 1 |
| Caputi, AP | 1 |
| Nakano, H | 1 |
| Magalang, UJ | 1 |
| Lee, SD | 1 |
| Krasney, JA | 1 |
| Farkas, GA | 1 |
| Bernini, GP | 2 |
| Argenio, GF | 2 |
| Vivaldi, MS | 2 |
| Del Corso, C | 2 |
| Birindelli, R | 1 |
| Luisi, M | 2 |
| Franchi, F | 2 |
| Sgrò, M | 1 |
1 trial available for ritanserin and Obesity
| Article | Year |
|---|---|
Impaired growth hormone response to insulin-induced hypoglycaemia in obese patients: restoration blocked by ritanserin after fenfluramine administration.
Topics: Adult; Blood Glucose; Female; Fenfluramine; Growth Hormone; Humans; Hypoglycemia; Insulin; Middle Ag | 1990 |
4 other studies available for ritanserin and Obesity
| Article | Year |
|---|---|
5-HT
Topics: Ergotamine; HEK293 Cells; Humans; Obesity; Protein Domains; Receptor, Serotonin, 5-HT2C; Ritanserin; | 2018 |
Anorectic activity of NG-nitro-L-arginine, an inhibitor of brain nitric oxide synthase, in obese Zucker rats.
Topics: Amino Acid Oxidoreductases; Animals; Appetite Depressants; Arginine; Body Weight; Brain; Eating; Mal | 1993 |
Serotonergic modulation of ventilation and upper airway stability in obese Zucker rats.
Topics: Age Factors; Analysis of Variance; Animals; Hypercapnia; Hyperoxia; Linear Models; Obesity; Plethysm | 2001 |
Effects of fenfluramine and ritanserin on prolactin response to insulin-induced hypoglycemia in obese patients: evidence for failure of the serotoninergic system.
Topics: Adolescent; Adult; Female; Fenfluramine; Humans; Hypoglycemia; Insulin; Middle Aged; Obesity; Piperi | 1989 |